Abbott Laboratories
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Robert Ford
- Full Time Employees
- 115,000
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 100 Abbott Park Road Abbott Park IL United States of America 60064-6400
- IPO Date
- Mar 17, 1980
- CIK
- 0000001800
- Website
- abbott.com
- Similar Companies
- Business
- Abbott Laboratories (NYSE: ABT) develops, manufactures, and sells a broad range of health care products worldwide. The company operates through four main segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices; its core offerings include branded generic pharmaceuticals such as Branded generics in emerging markets, anti-infectives, and gastrointestinal drugs; diagnostics encompassing point-of-care testing systems like i-STAT, molecular diagnostics via Alinity platforms, rapid diagnostics under BinaxNOW and Determine brands, and core laboratory instruments; nutritional products including pediatric formulas like Similac and Pediasure, adult nutritionals such as Ensure and Glucerna, and medical foods; as well as medical devices featuring cardiovascular and neuromodulation devices including FreeStyle Libre continuous glucose monitoring systems, Aveir leadless pacemakers, TactiFlex ablation catheters, and structural heart devices like Amplatzer occluders. Abbott serves health care professionals, consumers, hospitals, laboratories, and governments across more than 100 countries, with principal manufacturing facilities in the United States, Europe, Asia, and Latin America. Founded in 1888 and headquartered in Abbott Park, Illinois, the company maintains a diversified portfolio without notable subsidiaries or parent relationships impacting its core structure. In recent developments within the last two years, Abbott completed the acquisition of Cardiovascular Systems, Inc. in 2024 to expand its cardiovascular portfolio; launched the FreeStyle Libre 3 integrated continuous glucose monitoring sensor in multiple markets including the U.S.; introduced the AVEIR DR dual chamber leadless pacemaker system and the TactiFlex Sensor Enabled Ablation Catheter; formed strategic partnerships for digital health integrations and expanded diagnostics manufacturing capacity amid global demand surges; and reported strong growth in its diabetes and cardiovascular segments during 2025 earnings.
Company News
16,128 Shares in Abbott Laboratories $ABT Bought by Bank OZK
Abbott (ABT) Exceeds Market Returns: Some Facts to Consider
Aberdeen Wealth Management LLC Invests $843,000 in Abbott Laboratories $ABT
Jupiter Topco LLC Purchases Shares of 8,075,934 Abbott Laboratories $ABT
EFG International AG Buys New Position in Abbott Laboratories $ABT
Foyston Gordon & Payne Inc Makes New Investment in Abbott Laboratories $ABT
EP Wealth Advisors LLC Takes Position in Abbott Laboratories $ABT
Daiichi Life Insurance Co. Ltd. Buys Shares of 99,481 Abbott Laboratories $ABT
Clear Harbor Asset Management LLC Makes New $4.89 Million Investment in Abbott Laboratories $ABT
Haverford Trust Co Makes New Investment in Abbott Laboratories $ABT
5,665 Shares in Abbott Laboratories $ABT Acquired by Forefront Analytics LLC
Evolve Private Wealth LLC Purchases Shares of 23,207 Abbott Laboratories $ABT
Elevation Point Wealth Partners LLC Acquires Shares of 51,158 Abbott Laboratories $ABT
Commerce Bank Acquires Shares of 447,670 Abbott Laboratories $ABT
Connor Clark & Lunn Investment Management Ltd. Acquires New Shares in Abbott Laboratories $ABT
Two Recessions Couldn't Stop These 4 Healthcare Stocks From Raising Dividends
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
21,856 Shares in Abbott Laboratories $ABT Acquired by Fairtree Asset Management Pty Ltd
Advisors Capital Management LLC Purchases New Stake in Abbott Laboratories $ABT
Callan Family Office LLC Invests $8.55 Million in Abbott Laboratories $ABT